Publication: 130

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET
      QxMD      Google Scholar   
Citation:
Blood vol 117 (20) 5314-5320
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
360  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA032291, CA33601, CA77597, CA04457, U10 CA077658, CA77406, CA32291, CA29165, CA41287, CA03927, U10 CA031946, CA77651, U10 CA033601, CA59518, CA60138, CA26806, CA45389, U10 CA077597, CA45808, CA86726, U10 CA077440, CA77440, U10 CA077651, CA21060, CA47559, CA47642, CA45418, CA77658, CA77298, U10 CA047642, CA31983, CA31946, CA07968  
Corr. Author:
 
Authors:
                             
Networks:
 
Study
CALGB-50203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Clinical Trials and Observations, Lymphoid Neoplasia